Skip to main content

CASE REPORT article

Front. Cardiovasc. Med.
Sec. Cardio-Oncology
Volume 11 - 2024 | doi: 10.3389/fcvm.2024.1433668

A Case of Primary Pericardial Mesothelioma Treated with Multimodal Combined Therapy

Provisionally accepted
Jinlan Gong Jinlan Gong Xiaofeng Wu Xiaofeng Wu *Jiehua Wang Jiehua Wang *
  • Shanghai Shidong Hospital of Yangpu District, Shanghai, China

The final, formatted version of the article will be published soon.

    Primary pericardial mesothelioma (PMPM) is a rare, aggressive, and lethal form of cancer. It arises from pericardial mesothelial cells, with an incidence of less than 0.002%. Various risk factors contribute to this disease, such as asbestos exposure, viral infections, radiation exposure, immunodeficiency, and genetics. Clinical signs include constrictive pericarditis, pericardial effusion, and heart failure. Diagnosis relies on histopathological examination. PMPM is clinically rare with a poor prognosis, typically resulting in an average median survival time of 6-10 months. Currently, treatment lacks prospective evidence and specific clinical recommendations, relying on treatment experience documented in case reports. This report presents a case of PMPM in an adult female with atypical symptoms and explores the potential of multimodal combined therapy as a new treatment option.A 62-year-old female patient presented to our department in September 2023. The patient complained that she suffered from chest pain, right upper limb swelling and fatigue about one week. She was in the state of anxiety and depression for the last 8 years. She was a smoker consuming 1 pack of cigarettes every 4 days. She had no history of occupational asbestos exposure.A comprehensive medical history was conducted. In May 2023, the patient sought care at our hospital's fever clinic due to " lower fever and dry cough." Initially, a "respiratory tract infection" was suspected, and chest CT scan was performed and revealed irregular thickened pericardium (Fig. 1).

    Keywords: case report, Chest Pain, chemotherapy, PMPM, Lessened pericardial thickening

    Received: 16 May 2024; Accepted: 10 Sep 2024.

    Copyright: © 2024 Gong, Wu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xiaofeng Wu, Shanghai Shidong Hospital of Yangpu District, Shanghai, China
    Jiehua Wang, Shanghai Shidong Hospital of Yangpu District, Shanghai, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.